BRTX Files 8-K for Reg FD Disclosure, Exhibits on Feb 5

TL;DR

**BRTX filed an 8-K for Regulation FD disclosure and exhibits, signaling active communication.**

AI Summary

BioRestorative Therapies, Inc. (BRTX) filed an 8-K on February 5, 2024, to disclose information under Regulation FD and provide financial statements and exhibits. This filing indicates that the company is actively communicating with the public, likely regarding recent developments or upcoming events, as required by the SEC. For investors, this means the company is maintaining transparency, which can build confidence, but the specific content of the disclosure is not detailed in this summary, so further investigation into the exhibits is necessary to understand the full impact on the stock.

Why It Matters

This filing signals BioRestorative Therapies is adhering to disclosure requirements, which is crucial for maintaining investor trust and market transparency. Investors should review the full exhibits to understand the specific information being disclosed.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure filing and does not inherently present new risks, but the content of the exhibits could contain material information.

Analyst Insight

A smart investor would immediately seek out the full exhibits mentioned in this 8-K to understand the specific information disclosed under Regulation FD, as this could contain material news impacting the stock price.

Key Numbers

• 001-37603 — Commission File Number (identifies the company's filings with the SEC)
• 17 — Public Document Count (number of documents included in the filing)
• 11747 — Zip code (part of the registrant's business and mail address)
• 631-760-8100 — Business Phone Number (contact information for the registrant)
• $0.0001 — par value per share (par value of the Common Stock)

Key Players & Entities

• BioRestorative Therapies, Inc. (company) — the registrant filing the 8-K
• BRTX (company) — the trading symbol for BioRestorative Therapies, Inc.
• February 5, 2024 (date) — the date of the earliest event reported and filing date
• NASDAQ Capital Market (company) — the exchange where BRTX Common Stock is registered
• Nevada (company) — state of incorporation for BioRestorative Therapies, Inc.

Forward-Looking Statements

• BioRestorative Therapies will release specific details of the Regulation FD disclosure within the next week. (BioRestorative Therapies, Inc.) — medium confidence, target: 2024-02-12

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value BRTX NASDAQ Capital Marke

Filing Documents

• brt8k2524.htm (8-K) — 28KB
• ex99_1.htm (EX-99.1) — 12KB
• ex99_2.htm (EX-99.2) — 1KB
• poster.jpg (GRAPHIC) — 1336KB
• 0001021771-24-000027.txt ( ) — 2013KB
• brtx-20240205.xsd (EX-101.SCH) — 4KB
• brtx-20240205_lab.xml (EX-101.LAB) — 22KB
• brtx-20240205_pre.xml (EX-101.PRE) — 16KB
• brt8k2524_htm.xml (XML) — 4KB

01

Item 7.01 Regulation FD Disclosure . On February 5, 2024, BioRestorative Therapies, Inc. (the "Company") issued a press release (the "Press Release") announcing the public availability of a poster (the "Poster") titled "Autologous Stem Cell Therapy for Chronic Lumbar Disc Disease, Initial Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells". The Poster, which was presented on February 4, 2024 by the Company's Vice President of Research and Development, Francisco Silva, at the Orthopaedic Research Society (ORS) 2024 Annual Meeting (the "ORS Annual Meeting"), describes preliminary 26–52 week blinded data from the ongoing Phase 2 clinical trial of the Company's lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease. In the Press Release, the Company also announced again that it will hold a webcasted conference call with an associated slide presentation on February 5, 2024 at 8:30 a.m. ET to review the Poster. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company intends to use the Poster from time to time on and after February 4, 2024 in presentations about the Company's business. As indicated above, the Company used the Poster at the ORS Annual Meeting on February 4, 2024 and may use the Poster, possibly with modification, in other presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees and others with an interest in the Company and its business. The information contained in the Poster is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Poster speaks as of the date of this Current Report on Form 8-K. While the Company may elect to update the Poster in the future or reflect events and ci

Financial Statements and Exhibits

Financial Statements and Exhibits . (d) Exhibits . Number Description 99.1 Press release, dated February 5, 2024, issued by BioRestorative Therapies, Inc. 99.2 Poster 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: February 5, 2024 By: /s/ Lance Alstodt Lance Alstodt President and CEO

View Full Filing

View this 8-K filing on SEC EDGAR